Physician profile
Jeemin Eversole
NPI 1881125565
$606.68
in general payments reported to CMS, 2019-2025
12 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $328 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.01 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $104.85 | 2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $70.40 | 2024 | |
| Merck Sharp & Dohme LLC | $63.72 | 2024-2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Phathom Pharmaceuticals, INC. | $61.82 | 2024 | Voquezna |
| Ironshore Pharmaceuticals INC. | $49.21 | 2024 | |
| Glaxosmithkline, LLC. | $32.15 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $29.48 | 2024-2025 | Mounjaro, Zepbound |
| Viatris Specialty LLC | $23.97 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2024 | Rexulti |
| Amgen INC. | $17.64 | 2025 | Krystexxa |
| Radius Health, INC. | $16.57 | 2024 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeemin Eversole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.